CompanyGraphAt a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.86BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
2.24xvs all stocks
52-Week Change
200.42%vs all stocks
Market Capitalization
4.86BUSDvs all stocks (USD)
Enterprise Value
3.89BUSDvs all stocks (USD)
Forward P/E
-19.01xvs Biotechnology peers
Price to Book (MRQ)
5.29xvs Biotechnology peers
Enterprise to EBITDA
-25.03xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-20.64%vs Biotechnology peers
Return on Equity (TTM)
-64.09%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 27, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-353.78MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-167.95MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
7.61MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-166.31MUSDvs all stocks (USD)
Pre-tax Income
-183.79MUSDFY2025 · Dec 31, 2025Net Income
-183.79MUSDFY2025 · Dec 31, 2025EBIT
-178.31MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-155.35MUSDFY2025 · Dec 31, 2025Research & Development
117.67MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
48.64MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
10.96MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
5.48MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-183.79MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-158.68MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
257.84MUSDFY2025 · Dec 31, 2025Interest Paid
5.34MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-183.79MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
0.00USDFY2025 · Dec 31, 2025Stock-based Compensation
20.10MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.69MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
3.34MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-10.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-268.36MUSDFY2025 · Dec 31, 2025Sale of Investments
116.75MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-151.61MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
42.00MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-22.00MUSDFY2025 · Dec 31, 2025Other Financing Charges
-12.63MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
266.23MUSDFY2025 · Dec 31, 2025Shares Outstanding
132.74MSharesUpdated Sep 27, 2026Float Shares
123.61MSharesUpdated Sep 27, 2026Shares Short
11.79MSharesUpdated Sep 27, 2026Short Ratio
5.76daysvs all stocks
Short % of Shares Outstanding
8.83%vs all stocks
% Held by Insiders
2.02%vs all stocks
% Held by Institutions
88.31%vs all stocks
Total Cash (MRQ)
1.08BUSDvs all stocks (USD)
Total Cash per Share (MRQ)
8.07USDUpdated Sep 27, 2026Total Debt (MRQ)
36.47MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0397xvs Biotechnology peers
Current Ratio (MRQ)
6.95xvs Biotechnology peers
Book Value per Share (MRQ)
6.84USDUpdated Sep 27, 2026Total Assets
440.10MUSDvs all stocks (USD)
Total Current Assets
419.32MUSDFY2025 · Dec 31, 2025Total Liabilities
107.77MUSDFY2025 · Dec 31, 2025Total Non-current Assets
20.78MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
41.08MUSDFY2025 · Dec 31, 2025Total Current Liabilities
66.70MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
257.84MUSDFY2025 · Dec 31, 2025Other Short-term Investments
153.76MUSDFY2025 · Dec 31, 2025Accounts Payable
5.35MUSDFY2025 · Dec 31, 2025Other Current Liabilities
40.91MUSDFY2025 · Dec 31, 2025Long-term Debt
40.58MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
496.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
0.00USDFY2025 · Dec 31, 2025Retained Earnings
-582.67MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
332.33MUSDvs all stocks (USD)
52-Week Low
10.46USDUpdated Sep 27, 202652-Week High
49.70USDUpdated Sep 27, 202652-Week Change
200.42%vs all stocks
Beta
2.24xvs all stocks
50-Day MA
41.87USDUpdated Sep 27, 2026200-Day MA
26.66USDUpdated Sep 27, 2026Avg 10-Day Volume
2.77MSharesUpdated Sep 27, 2026Avg 30-Day Volume
2.02MSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-3.43USDUpdated Sep 27, 2026Other Income / Expense
-22.96MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 35,820,060.775
Market cap is $4.86B, above the global median of $1.2BNotable
Market cap (USD): 4,860,052,581Global Median: 1,201,862,193
Companies that share the same coordination system — how they create, deliver, or capture value.
Veradermics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai RAAS Blood Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing Tong Ren Tang Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Haemonetics Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Henlius Biotech, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Dianthus Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Iovance Biotherapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Erasca, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk